Fig. 6

Actionable alterations combined with overall survival for molecularly matched and unmatched therapies. A The molecular mutations and therapeutic regimens in advanced patients with DDR deficiency and detailed clinical and survival data. B Matched therapy significantly improved the OS of advanced patients with DDR mutations than those with unmatched therapy. Matched therapy was defined as precise treatment according to the molecular profiling of the individual patient (olaparib and platinum-based chemotherapy for DDR mutations, PD-1 blockade for positive PD-L1 expression). FOLFIRI: flurouracil and irinotecan. FOLFIRINOX: fluorouracil, irinotecan, and oxaliplatin. HIFU: high intensity focused ultrasound